Seattle Genetics continues to build pipeline

By Lisa Kerner

Charlotte, N.C., Oct. 17 - Seattle Genetics, Inc. president and chief executive office Clay B. Siegall said his company has a solid financial position on which to develop its robust pipeline of monoclonal cancer-fighting antibody products.

Siegall provided an overview of the company's products, including its two biggest drivers, SGN 40 and SGN 33, during a presentation at the 2006 BIO InvestorForum in San Francisco on Wednesday.

"We have steady milestone momentum over the next year with many product candidates in clinical trial," Siegall said. Ongoing studies include a combination study with SGN 33 and a phase 2 study with SGN 30, as well as a phase 1 study of SGN 25.

Siegall said that by retaining the worldwide rights to all of its antibody therapies and proprietary antibody-drug conjugate technology, Seattle Genetics can continue to add value to the programs and attract potential partners.

Partnerships had brought more than $50 million in cash payments to the Bothell, Wash., biotechnology company over the past several years, according to Siegall.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.